TCM
KALV

TCG Crossover Management’s KalVista Pharmaceuticals KALV Stock Holding History

TCG Crossover Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,163,356
Closed -$13.8M – 34
2024
Q1 		$13.8M Sell
1,163,356
-2,232,139
-66% -$29.8M 1.09% 26
2023
Q4 		$41.6M Hold
3,395,495
– – 4.61% 11
2023
Q3 		$32.7M Hold
3,395,495
– – 4.81% 7
2023
Q2 		$30.6M Hold
3,395,495
– – 5.01% 9
2023
Q1 		$26.7M Hold
3,395,495
– – 5.2% 7
2022
Q4 		$23M Buy
+3,395,495
New +$18.2M 4.05% 10

Other funds holding KALV

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TCG Crossover Management's KALV Position: Q2 2024 in Review

TCG Crossover Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2024, closing a stake of 1,163,356 shares — an estimated $13.8M sold.

TCG Crossover Management first reported a position in KALV in Q4 2022 and held it in 6 quarters. The position peaked at $41.6M in Q4 2023. 119 funds tracked by Wall St. Rank hold KALV as of Q2 2024.

  • TCG Crossover Management reported no remaining KalVista Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • TCG Crossover Management sold 1,163,356 KalVista Pharmaceuticals shares in Q2 2024, an estimated $13.8M.
  • TCG Crossover Management first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • TCG Crossover Management's KalVista Pharmaceuticals position peaked at $41.6M in Q4 2023.
  • 119 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2024.

Based on TCG Crossover Management's 13F filing for Q2 2024, filed 14 Aug 2024.